Sygnis puts cash to use, acquires C.B.S. Scientific

▤ Summary

Sygnis plans to acquire C.B.S. Scientific for $900,000 in cash and stock. C.B.S. makes life sciences research equipment such as gel electrophoresis machines and PCR workstations. Sygnis expects the deal to add immediate revenue and strengthen its position across genomic and proteomic workflows. The company also plans to combine locations and cut costs after previously buying another San Diego-based business. The acquisition reflects Sygnis’ strategy of using cash and equity to expand its life sciences product base.

▦ Linked Companies